KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $29.17 Consensus Target Price from Analysts

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has earned a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $29.1667.

KALV has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, October 8th. Citigroup reissued a “market outperform” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, November 11th. HC Wainwright raised their price objective on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a report on Friday, January 9th. Finally, Citizens Jmp decreased their price objective on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research report on Tuesday, November 11th.

KalVista Pharmaceuticals Trading Up 4.9%

NASDAQ:KALV opened at $15.31 on Friday. The firm has a market cap of $773.92 million, a PE ratio of -3.88 and a beta of -0.14. The stock has a fifty day moving average price of $15.16 and a 200 day moving average price of $13.79. KalVista Pharmaceuticals has a 12-month low of $8.25 and a 12-month high of $19.00. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share for the quarter, topping the consensus estimate of ($0.96) by $0.04. The company had revenue of $13.69 million for the quarter, compared to analysts’ expectations of $6.03 million. Sell-side analysts anticipate that KalVista Pharmaceuticals will post -3.56 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Brian Piekos sold 4,471 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $13.45, for a total transaction of $60,134.95. Following the completion of the sale, the chief financial officer owned 10,529 shares in the company, valued at $141,615.05. The trade was a 29.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Paul K. Audhya sold 5,296 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $13.45, for a total value of $71,231.20. Following the completion of the transaction, the insider directly owned 131,831 shares of the company’s stock, valued at $1,773,126.95. This trade represents a 3.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 31,329 shares of company stock valued at $437,371 in the last ninety days. Insiders own 4.30% of the company’s stock.

Institutional Trading of KalVista Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets grew its position in shares of KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in KalVista Pharmaceuticals in the third quarter valued at $55,000. Wolverine Asset Management LLC purchased a new position in shares of KalVista Pharmaceuticals during the third quarter worth about $57,000. KLP Kapitalforvaltning AS purchased a new position in shares of KalVista Pharmaceuticals during the third quarter worth about $63,000. Finally, Virtus Investment Advisers LLC acquired a new stake in shares of KalVista Pharmaceuticals during the second quarter worth about $81,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical?stage biotechnology company focused on the discovery and development of small?molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.